Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma

Molecular Biology of the Cell

Volumn 26, Issue 5, 2015, Pages 821-831

  Paccez, Juliano D ^a,b   Duncan, Kristal ^a,b   Vava, Akhona ^a,b   Correa, Ricardo G ^c   Libermann, Towia A ^d   Parker, M Iqbal ^a,b   Zerbini, Luiz F ^a,b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BURNHAM INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN AXL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; WORTMANNIN; AXL RECEPTOR TYROSINE KINASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INACTIVATION; EPITHELIUM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYME; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; ENZYMOLOGY; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; MICE, NUDE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84923824758     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-04-0868     Document Type: Article

References (64)

1. Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton Da, Hafizi S, Hanemann CO (2013). Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 33, 336-346.
2. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, Rustgi AK (2003). Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem 278, 1824-1830.
3. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2014). AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33, 1316-1324.
4. Bachelder RE, Yoon S-O, Franci C, de Herreros AG, Mercurio AM (2005). Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 168, 29-33.
5. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al. (2013). An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19, 279-290.
6. Cooper SC, Day R, Brooks C, Livings C, Thomson CS, Trudgill NJ (2009). The influence of deprivation and ethnicity on the incidence of esophageal cancer in England. Cancer Causes Control 20, 1459-1467.
7. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
8. Dirks W, Rome D, Ringel F, Jäger K, MacLeod Ra, Drexler HG (1999). Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk Res 23, 643-651.
9. Doble BW, Woodgett JR (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186.
10. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P (2011). Mechanisms of AXL overexpression and function in imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2, 874-885.
11. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 97, 11960-11965.
12. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917.
13. Gamliel Z (2000). Incidence, epidemiology, and etiology of esophageal cancer. Chest Surg Clin N Am 10, 441-450.
14. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon F-X, Pasquet J-M (2011). Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118, 2211-2221.
15. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107, 1124-1129.
16. Goruppi S, Ruaro E, Varnum B, Schneider C (1997). Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 17, 4442-4453.
17. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA (2007). Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67, 4219-4226.
18. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, Dahlbäck B (2009). Differential expression of Axl and Gas6 in renal cell carcinoma refl ecting tumor advancement and survival. Clin Cancer Res 15, 4742-4749.
19. Hafizi S, Dahlbäck B (2006a). Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 273, 5231-5244.
20. Hafizi S, Dahlbäck B (2006b). Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 17, 295-304.
21. Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong S, Haffner MC, Meeker AK, et al. (2010). The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10, 1009-1018.
22. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al. (2010). R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70, 1544-1554.
23. Hong J, Belkhiri A (2013). AXL mediates TRAIL resistance in esophageal adenocarcinoma. Neoplasia 15, 296-304.
24. Hong J, Peng D, Chen Z, Sehdev V, Belkhiri A (2013). ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res 73, 331-340.
25. Huang F, Hurlburt W, Greer A, Reeves Ka, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM (2010). Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 70, 7221-7231.
26. Iamaroon A, Krisanaprakornkit S (2009). Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol 45, e175-e179.
27. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, Bartram CR (1991). A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6, 2113-2120.
28. Karin M, Cao Y, Greten FR, Li Z-W (2002). NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2, 301-310.
29. Kim M, Datta A, Brakeman P, Yu W, Mostov KE (2007). Polarity proteins PAR6 and aPKC regulate cell death through GSK-3β in 3D epithelial morphogenesis. J Cell Sci 120, 2309-2317.
30. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A (2009). The Axl receptor tyrosine kinase confers an adverse prognostic infl uence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8, 618-626.
31. Lee WP, Wen Y, Varnum B, Hung M-C (2002). Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21, 329-336.
32. Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC, Cheung ALM (2007). Id-1 activation of PI3K/Akt/NFκB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 28, 2313-2320.
33. Li B, Li YY, Tsao SW, Cheung ALM (2009). Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther 8, 2635-2644.
34. Li Q, Verma IM (2002). NF-κB regulation in the immune system. Nat Rev Immunol 2, 725-734.
35. Linger RMA, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DHG, Lu X, Barón AE, Franklin WA, Merrick DT, et al. (2012). Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 1-12.
36. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin A-M, Gilmer TM (2009). Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69, 6871-6878.
37. Manfioletti G, Brancolini C, Avanzi G, Schneider C, Cascade C (1993). The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13, 4976-4985.
38. Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ (1996). Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 271, 9785-9789.
39. McCloskey P, Fridell YW, Attar E, Villa J, Jin Y, Varnum B, Liu ET (1997). GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem 272, 23285-23291.
40. McCloskey P, Pierce J, Koski RA, Varnum B, Liu ET (1994). Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ 5, 1105-1117.
41. Neubauer A, Burchert A, Maiwald C, Gruss HJ, Serke S, Huhn D, Wittig B, Liu E (1997). Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Leuk Lymphoma 25, 91-96.
42. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D (1994). Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84, 1931-1941.
43. Neubauer A, O'Bryan JP, Fiebeler A, Schmidt C, Huhn D, Liu ET (1993). Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. Semin Hematol 30, 34.
44. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R, Le Beau MM, Earp HS, Liu ET (1991). axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11, 5016-5031.
45. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, Bhasin M, Libermann Ta, Zerbini LF (2013). The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32, 689-698.
46. Paccez JD, Vogelsang M, Parker MI, Zerbini LF (2014). The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer 134, 1024-1033.
47. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ (2010). AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70, 7570-7579.
48. Ruan G-X, Kazlauskas A (2012). Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 31, 1692-1703.
49. Saito Y, Vandenheede JR, Cohen P (1994). The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem J 303, 27-31.
50. Shieh Y-S, Lai C-Y, Kao Y-R, Shiah S-G, Chu Y-W, Lee H-S, Wu C-W (2005). Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7, 1058-1064.
51. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta K, et al. (2010). GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127.
52. Somdyala NI, Bradshaw D, Gelderblom WC, Parkin DM (2010). Cancer incidence in a rural population of South Africa, 1998-2002. Int J Cancer 127, 2420-2429.
53. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB (2011). Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117, 734-743.
54. Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454.
55. Vazquez-Martin AI, Cufí S, Oliveras-Ferraros C, Torres-Garcia VZ, Corominas-Faja B, Cuyàs El, Bonavia R, Visa J, Martin-Castillo B, Barrajón-Catalán E, et al. (2013). IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 3, 2560.
56. Veale RB, Thornley AL (1984). Atypical cytokeratins synthesized by human oesophageal carcinoma cells in culture. S Afr J Sci 80, 260-267.
57. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi J-P, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J (2011). Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30, 1436-1448.
58. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M (2001). Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37, 2264-2274.
59. Wu H-T, Ko S-Y, Fong JH-J, Chang K-W, Liu T-Y, Kao S-Y (2009). Expression of phosphorylated Akt in oral carcinogenesis and its induction by nicotine and alkaline stimulation. J Oral Pathol Med 38, 206-213.
60. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho J, Ijiri K, Wei W, Joseph M, Gu X, Grall F, et al. (2004). NF-κB-mediated repression of growth arrest- and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survival. Proc Natl Acad Sci USA 101, 13618-13623.
61. Zerbini LF, Czibere A, Wang Y, Correa RG, Otu H, Joseph M, Takayasu Y, Silver M, Gu X, Ruchusatsawat K, et al. (2006). A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res 66, 11922-11931.
62. Zerbini LF, Wang Y, Cho J-YY, Libermann TA (2003). Constitutive activation of nuclear factor κB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63, 2206-2215.
63. Zhang Y-X, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A (2008). AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68, 1905-1915.
64. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. (2012). Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44, 852-860.